SUDEEPPHRMBSESudeep Pharma LtdHighPositive
Announced Thu, 21 May · 16:46 IST

This is to inform that the Board has recommended Rs. 1.50/-dividend per Equity Share for the Financial Year 2025-26

Corporate Actions View source PDF

SUDEEPPHRM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.7%1-day move
₹665.00
prior close
₹656.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.7-1.3-1.2-0.2+4.7+4.7+1.5+11.6+16.8+15.2+23.2+24.7+27.1
Up moveDown movePending
AI summary

Sudeep Pharma's Board has recommended a final dividend of Rs. 1.50 per equity share (150% on face value of Rs. 1) for FY 2025-26, subject to shareholder approval at the forthcoming AGM. The company reported robust FY2025-26 results with consolidated revenue from operations of Rs. 6,422.58 crore, up 28% YoY from Rs. 5,020 crore. Consolidated profit after tax grew 25.5% to Rs. 1,742.85 crore from Rs. 1,387.29 crore. EPS improved to Rs. 15.50 per share from Rs. 12.79. The company completed its IPO in November 2025 and recently acquired Nutrition Supplier & Services (Ireland) Limited as a step-down subsidiary.

Likely market impact

The 150% dividend payout signals financial health and shareholder-friendly policies. Combined with strong 25%+ profit growth, this could support the stock price near-term pending shareholder approval at AGM.